Nilotinib-induced Diabetes in Japanese Patients with Chronic Myeloid Leukemia-Reference-Cited by-同舟云学术

Nilotinib-induced Diabetes in Japanese Patients with Chronic Myeloid Leukemia

Published:2024 Issue: Volume: Page:
ISSN:0918-2918
Container-title:Internal Medicine
language:en
Short-container-title:Intern. Med.

Author:

Iwamoto Yuichiro¹,Kimura Tomohiko¹,Iwamoto Hideyuki¹,Sanada Junpei¹,Fushimi Yoshiro¹,Katakura Yukino¹,Shimoda Masashi¹,Kondo Toshinori²,Nakanishi Shuhei¹,Mune Tomoatsu¹,Kaku Kohei¹,Wada Hideho²,Kaneto Hideaki¹

Affiliation:

1. Department of Diabetes, Metabolism and Endocrinology, Kawasaki Medical School, Japan

2. Department of Hematology, Kawasaki Medical School, Japan

Publisher

Japanese Society of Internal Medicine

Link

https://www.jstage.jst.go.jp/article/internalmedicine/advpub/0/advpub_3740-24/_pdf

Reference31 articles.

1. 1. Ciftciler R, Haznedaroglu IC. Tailored tyrosine kinase inhibitor (TKI) treatment of chronic myeloid leukemia (CML) based on current evidence. Eur Rev Med Pharmacol Sci 25: 7787-7798, 2021.

2. 2. Hartmann JT, Haap M, Kopp HG, Lipp HP. Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects. Curr Drug Metab 10: 470-481, 2009.

3. 3. Ismail AS, Yassin MA. Nilotinib-Induced Diabetes Mellitus in a Young Female with Chronic Myeloid Leukemia. Cureus 12: e10277, 2020.

4. 4. Nakamae H, Yamamoto M, Sakaida E, et al. Nilotinib vs. imatinib in Japanese patients with newly diagnosed chronic myeloid leukemia in chronic phase: 10-year follow-up of the Japanese subgroup of the randomized ENESTnd trial. Int J Hematol 115: 33-42, 2022.

5. 5. Franklin M, Burns L, Perez S, Yerragolam D, Makenbaeva D. Incidence of type 2 diabetes mellitus and hyperlipidemia in patients prescribed dasatinib or nilotinib as first- or second-line therapy for chronic myelogenous leukemia in the US. Curr Med Res Opin 34: 353-360, 2018.